The purpose of this multi-center,single arm,phase Ⅱ clinical trail is to determine the safety and efficacy of GVD±R (gemcitabine, oral vinorelbine and doxorubicin liposome, with or without rituximab) regimen for autologous hematopoietic stem cell transplantation(ASCT)-eligible patients with refractory/relapsed diffuse large B-cell lymphoma.

Inclusion Criteria:

• biopsy proved CD20+ DLBCL;
• previously received at least one systemic treatment (including chemotherapy) without remission or relapse after remission;
• at least one evaluable lesion；
• ECOG PS 0-1;
• 18-65 years;
• proper functioning of the major organs.

Exclusion Criteria:

• involvement of central nervous system;
• with other malignancy;
• patients receiving or received drug of other clinical trial within 30 days；
• previously received doxorubicin liposome or have used other anthracycline drug with accumulated restricted doses (adriamycin 450mg/m2, epirubicin 935mg/m2, acrarubicin 900mg/m2)；
• patients who received treatment for hematologic toxicity caused by previous chemotherapy within 7 days before enrollment;
• grade 2 or more peripheral neuropathy.